ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ラニチジン

Ranisen

HCID 5039
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
66357-35-5
標準SMILES
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
InChIKey
VMXUWOKSQNHOCA-UHFFFAOYSA-N
分子式
C13H22N4O3S
平均分子量
314.41 g/mol
単同位体質量
314.14126175

概要

Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations. The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.

名称と識別子

優先名称
Ranisen
IUPAC
1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
現地名
ラニチジン
英語名
Ranitidine
分子式
C13H22N4O3S
分子量
314.4

名称と別名

AchedosDuractinIstomarMicrotidPtinolinQuicranRadinatRanidineRaniogasRanisenRaniterRanitiget
名称をさらに表示
N-[1-(メチルアミノ)-2-ニトロエテニル]-2-[5-(ジメチルアミノメチル)フラン-2-イルメチルチオ]エタンアミンラニチジンN-[2-[[[5-[(ジメチルアミノ)メチル]-2-フラニル]メチル]チオ]エチル]-N'-メチル-2-ニトロ-1,1-エテンジアミン1-(メチルアミノ)-1-[[2-[[5-(ジメチルアミノメチル)-2-フリル]メチルチオ]エチル]アミノ]-2-ニトロエテンN-[2-[[5-[(ジメチルアミノ)メチル]フルフリル]チオ]エチル]-N'-メチル-2-ニトロ-1,1-エテンジアミンRANITIDINE BASERanitidinTriggerRANITIDINE USPRNDU1cexTauralZantaeZanticSampep
RantacidRaticinaUlceraninUrantacVerlostVizerulWeichilinXanidine

データベース識別子

CAS
66357-35-5
PubChem CID
5039

物性

構造計算による物性

XLogP
0.3
極性表面積
112 Ų
水素結合供与体数
2
水素結合受容体数
7
回転可能結合数
9
重原子数
21
形式電荷
0
複雑度
347

実験および物理化学的性質

DrugsPharmaceuticals -> Antiulcer Drugs
LogP0.64
Solubilitysoluble in water
Dissociation Constants · 2 件

8.31

8.2 and 2.7

Collision Cross Section169.0 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID8045191]

物理化学的性質

融点
69 · 69-70°C
沸点
437.1 · 437.1±45.0 °C(Predicted)
比重(密度)
1.184 · 1.184±0.06 g/cm3(Predicted)
貯蔵温度
4 °C · Desiccate at +4°C
溶解性
2 O: · H2O: 1.8 mg/mL
酸解離定数(Pka)
2.19 · pKa 2.19±0.04 (Uncertain)
外見
個体
色
タン
水溶解度
24.7 mg/mL · 24.7mg/mL
安定性
吸湿性

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

安全データ

wgk
2
rtecs
KM6557000
毒性
LD50 oral in rat: > 5gm/kg
safety_code
22-24/25
有毒物質データの
66357-35-5(Hazardous Substances Data)

化学と産業

薬理情報

ATC CodeA02BA02
Protein BindingThe plasma protein binding of ranitidine is approximately 15%.
Pharmacodynamics · 1 件

Ranitidine decreases the secretion of gastric acid stimulated by food and drugs. It also reduces the secretion of gastric acid in hypersecretory conditions such as Zollinger-Ellison syndrome. Marked improvements in the appearance of the esophageal tissues have been observed by endoscopic imaging after ranitidine therapy.

Mechanism of Action · 1 件

After a meal, the hormone gastrin, produced by cells in the lining of the stomach, stimulates the release of histamine, which then binds to histamine H2 receptors, leading to the secretion of gastric acid. Ranitidine reduces the secretion of gastric acid by reversible binding to histamine (H2) receptors, which are found on gastric parietal cells. This process leads to the inhibition of histamine binding to this receptor, causing the reduction of gastric acid secretion. The relief of gastric-acid related symptoms can occur as soon as 60 minutes after administration of a single dose, and the effects can last from 4-10 hours, providing fast and effective symptomatic relief.

Biological Half-Life · 1 件

The elimination half-life or ranitidine is about 2.5-3 hours. It may be longer after oral administration versus injection. The plasma half-life is longer for elderly patients population due to a decrease in renal function, and is measured at 3-4 hours.

Metabolism/Metabolites · 1 件

The major metabolite in the urine is N-oxide, which represents less than 4% of the dose. Other metabolites of ranitidine include S-oxide (1%) and desmethyl ranitidine (1%). The feces contain the remainder of the excreted ranitidine dose. Liver dysfunction has been shown to cause small, but clinically insignificant, changes in various ranitidine pharmacokinetic parameters.

Absorption, Distribution and Excretion · 4 件

関連反応

67 件
反応記録を作成
HRID 24285 の反応式
HRID 24285反応物として
HRID 24286 の反応式
HRID 24286反応物として
HRID 53909 の反応式
HRID 53909反応物として
HRID 53910 の反応式
HRID 53910反応物として
HRID 53911 の反応式
HRID 53911反応物として
HRID 53912 の反応式
HRID 53912反応物として
HRID 53913 の反応式
HRID 53913反応物として
HRID 65761 の反応式
HRID 65761生成物として
前へ1 / 9 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
DTXSID
DTXSID8045191
ChEMBL
CHEMBL1790041
UNII
884KT10YB7
CAS データベース
66357 · 66357-35-5(CAS DataBase Reference)
NISTの化学物質情報
Ranitidine(66357-35-5)
EPAの化学物質情報
1 · 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- (66357-35-5)

Ranitidine is rapidly absorbed with peak concentrations reached within 1-3 hours after administration, and varying greatly among patients. Bioavailability is about 50%-60% due to hepatic metabolism. In a pharmacokinetic study of healthy males, the AUC 0-infinity was about 2,488.6 ng x h/mL and the median Tmax was 2.83 hours. Food or antacids have limited effects on absorption. One clinical study found that the administration of a potent antacid (150 mmol) in subjects in the fasted state led to decreased absorption of ranitidine.

This drug is mainly excreted in the urine but also excreted in the feces. About 30% of a single oral dose has been measured in the urine as unchanged drug within 24 hours of ingestion.

The volume of distribution is higher than body volume, and measures at approximately 1.4 L/kg. It concentrates in breast milk, but does not readily distribute into the cerebrospinal fluid.

Renal clearance is about 410 mL/min according to FDA prescribing information. Another resource mentions a plasma clearance of approximately 600 ml/min. Clearance is decreased in the elderly and those with impaired or hepatic renal function. It is recommended to decrease the dose of ranitidine by one-half in patients with renal impairment.

応用分野 · 5 件

用途ラニチジン(英: Ranitidine、開発コードAH19065)は、ヒスタミンH2受容体拮抗薬の一つである。壁細胞のH2受容体を遮断することにより胃酸分泌を抑制するため、胃酸分泌抑制薬として使用される。商品名ザンタック。消化性潰瘍、胃食道逆流症、Zollinger–Ellison症候群(英語版)の治療に使用される他、蕁麻疹の治療で有効であるとの報告がある。

説明Ranitidine, a H2-receptor agonist, caused contact dermatitis within the pharmaceutical industry.

来歴Ranitidine was first prepared in England as AH19065 by John Bradshaw in the summer of 1977 in the Ware research laboratories of Allen and Hanburys, part of the former Glaxo organisation.Glaxo refined the model further, by replacing the imidazole ring of cimetidine with a furan ring with a nitrogen-containing substituent, and in doing so developed ranitidine. Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and 10 times the activity of cimetidine. Ranitidine was introduced in 1981, and was the world's biggest-selling prescription drug by 1987. Subsequently, it was largely superseded by the more effective proton-pump inhibitor (PPI) class of drugs, with omeprazole becoming the biggest-selling drug for many years.In September 2019, the probable carcinogen N-nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls; in April 2020, it was withdrawn from the United States market and suspended in Europe and Australia. In 2024, ranitidine was re-approved for sale in Australia after the local sponsor of Zantac changed suppliers and tablet formulation. The new formulation was demonstrated to be stable throughout its shelf life and that nitrosamines are controlled within internationally established acceptable intake limits applied to the maximum daily dose.

使用Ranitidine (cas# 66357-35-5) was used as a standard for testing the therapeutic effect of brown propolis extract against aspirin and ethanol- induced gastric ulcers.

一般的な説明Ranitidine, N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thiol] ethyl]-N'-methyl-2-nitro-l,1-ethenediamine (Zantac), is a white solid, which inits hydrochloride salt form is highly soluble in water. It is anaminoalkyl furan derivative with pKa values of 2.7 (sidechain) and 8.2 (dimethylamino). Ranitidine is more potentthan cimetidine, but less potent than famotidine. Likeother H2-antagonists, it does not appear to bind to otherreceptors.Bioavailability of an oral dose of ranitidine is about 50%and is not significantly affected by the presence of food.Some antacids may reduce ranitidine absorption and shouldnot be taken within 1 hour of administration of this drug. Theplasma half-life of the drug is 2 to 3 hours, and it is excretedalong with its metabolites in the urine. Three metabolites, ranitidineN-oxide, ranitidine S-oxide, and desmethyl ranitidine,have been identified. Ranitidine is only a weak inhibitor ofthe hepatic cytochrome isozymes, and recommended doses ofthe drug do not appear to inhibit the metabolism of otherdrugs. However, there have been isolated reports of drug interactions(warfarin, triazolam) that suggest that ranitidinemay affect the bioavailability of certain drugs by someunidentified mechanism, perhaps by pH-dependent effect onabsorption or a change in volume of distribution.In addition to being available in various dosage forms asthe hydrochloride salt, ranitidine is also available as a bismuthcitrate salt for use with the macrolide antibiotic clarithromycinin treating patients with an active duodenalulcer associated with H. pylori infection. Eradication of H.pylori reduces the risk of duodenal ulcer recurrence.

上流・下流製品情報

上流原料

ニトロエテンメチルスルフィドL-システインフルフリルアルコール4-メチル-2-ペンタノン2,2'-チオビス(エチルアミン)N,N-ジメチル-2-フランメタンアミン2-(Nitromethylene)thiazolidine1-メチルアミノ-1-メチルチオ-2-ニトロエチレン5-[(ジメチルアミノ)メチル]-2-フランメタノール1,1-dichloro-2-nitroethene5-(2-アミノエチルチオメチル)-N,N-ジメチル-2-フランメタンアミン1,4-ジオキサン2-アミノエタンチオール塩酸塩